You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》樂普生物(02157.HK)暗盤平開報7.13元
阿思達克 02-22 16:20
根據輝立交易平臺顯示,明天掛牌的樂普生物-B(02157.HK)暗盤平開報7.13元欠承接,低見6.7元,現報7.05元,較上市價7.13元,低1.1%,成交17萬股。 樂普生物是一家聚焦於腫瘤治療領域的創新型生物製藥企業,並已構建了多個產品管線。是次上市共發售近1.27億股,並已引入維梧資本及King Star爲基石投資者,合共認購5,464.8萬股;其中10%公開發售獲4.65倍超購,認購一手中籤率22.3%,股份以招股範圍(6.87-7.38元)中間位定價,料集資淨額約8.04億元,其中約68.5%擬用於發展核心產品撥資、6.3%用於其他主要臨牀階段候選藥物和主要臨牀前候選藥物、15.8%用於收購有潛力技術及資產及擴張候選藥物管線。上市聯席保薦人分別爲中金及大摩。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account